Moreover, we propose an immunometabolic therapeutic approach targeting cholesterol efflux in TAMs through OV-targeted ApoA1 delivery, which has been proven effective and safe for GBM treatment and can be translated to other preclinical or clinical cancer therapies. Here, APOA1 is linked to cancer.